Biosimilars

Our extensive Hatch-Waxman litigation practice and successful practice in post-grant PTO proceedings, combined with our deep technical expertise in biotechnology, uniquely positions us to develop and implement effective IP strategies for biosimilars. This industry-specific expertise is backed by one of the largest and most experienced biotechnology groups in IP law, with more than 75 attorneys and scientists representing clients in all stages of their business and technology development, as well a talented litigation group adept in all aspects of biotechnology IP law.

Our attorneys have the bench strength to help you successfully navigate the biosimilars pathway.

Up-to-date knowledge of biosimilars legislation

IP litigators with numerous trial and appellate successes

Extensive Hatch-Waxman litigation experience

Successful Post-Grant PTO practice on behalf of patent owners and petitioners

Over 20 attorneys with PhD’s in the life sciences

Extensive experience in biologics patent prosecution

Licensing and other transactional experience related to biologics

Count on our deep expertise across a spectrum of technologies.

Antibodies & Immunology

Biologics

Peptides

Research Tools & Reagents

Therapeutics

Biological Manufacturing of Chemicals

Diagnostic Tools

Personalized Medicine

Stem Cells & Regenerative Medicine

Vaccines

Representative Engagements

Australia National University

California Institute of Technology

Capricor

Chrontech Pharma

Creative Peptides Sweden AB

Cytori Therapeutics

Eppendorf AG

Harvard University

Healthgen Biotechnology, Inc. in Wuhan

Hitachi Chemical Research Center

Illumina

Imagine AB

ISIS Pharmaceuticals

Kyoto University

The National Institutes of Health

Stanford University

The University of California (UCSD, UCI, UCLA, UCSF)

Attorneys Jonathan Bachand and William Adams co-authored "What Celgene Corp. v. Peter Means For Biosimilar Developers," which was published on the Biosimilar Development website. Excerpt: A recent...
World Biosimilar Congress Europe 2019
Partner Jonathan Bachand was quoted in 'When Can Biologic Patent Disputes Go Before the ITC?' an article published by The Center for Biosimilars Excerpt: The ITC has 2 remedies available to enforce...